Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nepafenac 0.3% for diabetic cataract surgery outcomes
NCT01872611Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jun 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in macular edema comparing Nepafenac with Vehicle (2 arms). Primary endpoints: Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of >= 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90 and Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery. Started Jun 2013; status: completed.
02
Drugs
nepafenac
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01872611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01872611.